Assessment of Pembrolizumab Therapy for the Treatment of Microsatellite Instability–High Gastric or Gastroesophageal Junction Cancer Among Patients in the KEYNOTE-059, KEYNOTE-061, and KEYNOTE-062 Clinical Trials

Chao, Joseph; S. Fuchs, Charles; Shitara, Kohei; Tabernero, Josep; Muro, Kei; Van Cutsem, Eric; Bang, Yung‐Jue; De Vita, Ferdinando; Landers, Gregory; Yen, Chia‐Jui; Chau, Ian; Elme, Anneli; Lee, Jeeyun; Özgüroğlu, Mustafa; V.T. Catenacci, Daniel; H. Yoon, Harry; Chen, Erluo; E. Adelberg, David; Shih, Chie‐Schin; Shah, Sukrut; Bhagia, Pooja; A. Wainberg, Zev

doi:10.1001/jamaoncol.2021.0275

Public

Assessment of Pembrolizumab Therapy for the Treatment of Microsatellite Instability–High Gastric or Gastroesophageal Junction Cancer Among Patients in the KEYNOTE-059, KEYNOTE-061, and KEYNOTE-062 Clinical Trials

Published in JAMA Oncology • Apr 1, 2021

Authors:

Joseph Chao

Charles S. Fuchs

Kohei Shitara

Abstract

IMPORTANCE: Immunotherapy has been associated with improved outcomes among patients who have received previous treatment for microsatellite instability-high (MSI-H) tumors. OBJECTIVE: To evaluate the antitumor activity of pembrolizumab therapy vs chemotherapy among patients with MSI-H advanced gastr...

Subject

Pembrolizumab

Medicine

Capecitabine

Research Assistant

AI chat, annotations, notes & similar papers

Finding related papers...

Discussions

(0)

No comments yet

Be the first to share your thoughts!